- ￥772 - 9360
- TargetMol
- T67706
- 2026年07月07日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- CAS号：
1144075-36-4
- 规格：
1mg/5mg/10mg/25mg/50mg/100mg/200mg
| 规格： | 1mg | 产品价格： | ￥772.0 |
|---|---|---|---|
| 规格： | 5mg | 产品价格： | ￥1864.0 |
| 规格： | 10mg | 产品价格： | ￥2608.0 |
| 规格： | 25mg | 产品价格： | ￥3864.0 |
| 规格： | 50mg | 产品价格： | ￥5240.0 |
| 规格： | 100mg | 产品价格： | ￥6888.0 |
| 规格： | 200mg | 产品价格： | ￥9360.0 |
Product Introduction
Bioactivity
| 名称 | mTOR inhibitor 9c |
| 描述 | mTOR inhibitor 9c is a selective mTOR inhibitor with IC50 of 0.7nM and 825nM for mTOR and PI3Kα, respectively. |
| 体外活性 | mTOR inhibitor 9c以87nM的IC50值抑制LNCaP细胞的生长[1]。 |
| 存储条件 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| 溶解度 | DMSO : 60 mg/mL (140.35 mM), Sonication is recommended. |
| 关键字 | PI3Kα | mTOR inhibitor 9c | mTOR |
| 相关产品 | Creatine monohydrate | L-Proline | Musk ketone | Metformin | Quercetin | Hyaluronic acid | Methyl eugenol | L-Leucine | Dihydromyricetin | Myricetin | Isoprenaline hydrochloride | Stearamide |
| 相关库 | Inhibitor Library | Anti-Breast Cancer Compound Library | Angiogenesis related Compound Library | Bioactive Compound Library | Bioactive Compounds Library Max | Autophagy Compound Library | Kinase Inhibitor Library | Anti-Aging Compound Library | Anti-Liver Cancer Compound Library | Anti-Ovarian Cancer Compound Library | Hematonosis Compound Library | Immunology/Inflammation Compound Library |
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The mammalian target of rapamycin (mTOR) is the catalytic subunit of two multiprotein complexes, mTOR complex-1 (mTORC1) and mTOR complex-2 (mTORC2). Clinically used rapamycin and rapalogs are FKBP12-dependent allosteric inhibitors of mTORC
Expanding Human T Regulatory Cells with the mTOR-Inhibitor Rapamycin
CD4+ CD25+ FOXP3+ T regulatory (Treg) cells are pivotal for the induction and maintenance of peripheral tolerance in both mice and humans. The possibility to use Treg cells for the treatment of T-cell-mediated diseases has recently gained
Development of ATP-Competitive mTOR Inhibitors
mTOR inhibitor rapamycin and structurally related rapalogs have failed to show significant single-agent antitumor efficacy in most types of cancer. This limited clinical success may be due to the inability of the rapalogs to maintain a complete blockade
技术资料暂无技术资料 索取技术资料
